Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 247M 221M 204M 186M 349M 23.46B 354M 2.45B 964M 12.26B 928M 909M 39.19B P/E 2026 *
-16.3x
P/E 2027 * -7.62x
Enterprise Value 247M 221M 204M 186M 349M 23.46B 354M 2.45B 964M 12.26B 928M 909M 39.19B EV / Sales 2026 *
16.3x
EV / Sales 2027 * 14.7x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day-2.79%
1 week-0.43%
Current month-0.60%
1 month-5.94%
3 months-13.64%
6 months-42.42%
Current year-43.11%
1 week 0.89
Extreme 0.8902
1
1 month 0.88
Extreme 0.8823
1.05
Current year 0.88
Extreme 0.8823
1.98
1 year 0.88
Extreme 0.8823
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
3.96
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Date Insider Type Main position Quantity % Market Cap. Importance
7/1/26 Free

Director

125,000 0.0501%
7/1/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
7/1/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
-2.99%-0.43%-42.07%-19.49% 247M
+1.52%-7.16%+51.66%+67.41% 65B
+1.52%+6.83%+10.89%+79.30% 51.2B
+0.30%-0.46%-0.03%+61.89% 51.19B
-0.65%+1.02%+24.91%+41.84% 43.93B
+0.79%+5.96%+16.54%+134.00% 41.96B
+2.65%-5.71%+238.59%+530.59% 38.14B
+2.16%+10.36%+18.92%+59.70% 33.24B
-0.90%-10.49%+37.09%+1.80% 25.2B
+1.60%+2.21%+27.96%+28.00% 22.5B
Average +0.59%-0.03%+38.45%+98.50% 37.26B
Weighted average by Cap. +0.98%+0.04%+45.58%+112.62%

Financials

2026 *2027 *
Net sales 15.19M 13.54M 12.55M 11.41M 21.4M 1.44B 21.76M 150M 59.17M 753M 57M 55.81M 2.41B 16.83M 15.01M 13.9M 12.64M 23.72M 1.6B 24.11M 167M 65.56M 834M 63.16M 61.84M 2.67B
Net income -22.64M -20.18M -18.7M -17M -31.9M -2.15B -32.42M -224M -88.18M -1.12B -84.94M -83.17M -3.59B -34.44M -30.7M -28.44M -25.86M -48.52M -3.27B -49.32M -341M -134M -1.71B -129M -127M -5.46B
Net Debt - -
Projected Income Statement - Annual - Lineage Cell Therapeutics, Inc.
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
26-10-19 US$0.9499 -2.90% 518,308
26-10-16 US$0.9783 -1.21% 1,308,653
26-10-15 US$0.9903 +7.93% 1,424,713
26-10-14 US$0.9175 +1.01% 2,201,249
26-10-13 US$0.9083 -4.80% 1,784,674
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lineage Cell Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.9783USD
Average target price
5.500USD
Spread / Average Target
+462.20%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lineage Cell Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LCTX Stock